Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Single Arm Study of CarbopLatin Plus Etoposide With Bevacizumab and Atezolizumab in Patients With exTEnded-disease Small-cell Lung Cancer (SCLC)

NCT04730999 is registered in ClinicalTrials.gov with Gruppo Oncologico Italiano di Ricerca Clinica as lead sponsor.

NCT NCT04730999
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04730999 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Single Arm Study of CarbopLatin Plus Etoposide With Bevacizumab and Atezolizumab in Patients With exTEnded-disease Small-cell Lung Cancer (SCLC)
Lead sponsor
Gruppo Oncologico Italiano di Ricerca Clinica
Phase
Phase 2
Overall status
Completed
Start date
July 1, 2020
Completion date
June 19, 2024
Enrollment
54 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung cancer